ProFibrix, a Netherlands-based developer of products that help stop bleeding after surgery, has raised $22m in equity and debt by extending its series B round and promoted Jan Ohrstrom to chief executive (CEO).
The round was co-led by venture capital firm Vesalius Biocapital and Inkef Capital, a quasi-corporate venturing joint venture between pension funds ABP and Omers in its first deal after being set up in June last year.
They were joined in the consortium by VC firms Index Ventures and Gilde Healthcare Partners.
In August 2009, ProFibrix raised $11m from Gilde and Index for its B round, the same amount it had raised in March 2007’s A round led by Index.
Jaap Koopman, founding CEO of ProFibrix, will become chief scientific officer.